Technical Analysis for 0ND5 - H Lundbeck A/S
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 173.73 | 0.00% | 0.00 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | 0.59% | |
| New 52 Week High | Strength | 0.59% | |
| Hot IPO Pullback | Bullish Swing Setup | 5.02% | |
| New 52 Week Closing High | Bullish | 1.36% | |
| New 52 Week High | Strength | 1.36% | |
| Hot IPO Pullback | Bullish Swing Setup | 6.53% | |
| NR7 | Range Contraction | 6.53% |
Get a Trading Sidekick!
H Lundbeck A/S Description
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
Classification
Keywords: Pharmaceuticals Drugs Biopharmaceutical Alzheimer's Disease Parkinson's Disease Psychoactive Drugs Mood Stabilizers Epilepsy Schizophrenia Depression Huntington's Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 174.5 |
| 52 Week Low | 148.6 |
| Average Volume | 120,687 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 168.01 |
| Average True Range | 6.22 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 34.35 |
| -DI | 12.05 |
| Chandelier Exit (Long, 3 ATRs) | 155.84 |
| Chandelier Exit (Short, 3 ATRs) | 167.26 |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 2.52 |
| MACD Signal Line | 1.20 |
| MACD Histogram | 1.3235 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 178.68 | ||||
| Resistance 3 (R3) | 178.38 | 176.44 | 177.85 | ||
| Resistance 2 (R2) | 176.44 | 175.18 | 176.59 | 177.57 | |
| Resistance 1 (R1) | 175.08 | 174.40 | 175.76 | 175.38 | 177.30 |
| Pivot Point | 173.14 | 173.14 | 173.48 | 173.29 | 173.14 |
| Support 1 (S1) | 171.78 | 171.88 | 172.46 | 172.08 | 170.15 |
| Support 2 (S2) | 169.84 | 171.10 | 169.99 | 169.88 | |
| Support 3 (S3) | 168.48 | 169.84 | 169.60 | ||
| Support 4 (S4) | 168.78 |
